Review





Similar Products

hydrocortisone  (PromoCell)
96
PromoCell hydrocortisone
Hydrocortisone, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+%E2%97%A6c/Endothelial+Cell+Growth+Medium+MV+2+KIT/pmc13019081-439-15-16
Average 96 stars, based on 1 article reviews
hydrocortisone - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
adu s100  (MedChemExpress)
96
MedChemExpress adu s100
(A) Experimental design. All mice received two doses of HSV-1 gD mRNA administered one week apart. Mice were then assigned to receive PBS, mRNA-UB-E6/E7-gD, <t>ADU-S100,</t> or ADU-S100 + mRNA-UB-E6/E7-gD. One week after the final vaccination, mice were challenged subcutaneously with TC-1 cells. ADU-S100 (10 μg/dose) was administered intratumorally beginning 7 days after tumor implantation, when tumors reached approximately 5 × 5 mm, for a total of three treatments. (B) Tumor volumes of individual mice at the experimental endpoint. (C) Kaplan–Meier survival analysis of the indicated treatment groups. (D) Cytotoxic T-lymphocyte (CTL) activity against TC-1 target cells measured 24 h after assay initiation. Effector-to-target (E) ratios are indicated. (E) IFN-γ production in splenocyte culture supernatants measured by ELISA 24 h after assay initiation. E ratios are indicated. (F, G) Flow cytometric analysis of HPV16 E7-specific CD8 + T cells in tumor-infiltrating lymphocytes (F) and splenocytes (G), determined by HPV16 E7 tetramer staining. (H) Quantification of CD4 + and CD8 + tumor-infiltrating cells by immunohistochemistry. Positive cells were quantified using ImageJ from randomly selected microscopic fields and expressed as the number of positive cells per field. Statistical significance: ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Adu S100, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+%E2%97%A6c/2%E2%80%993%E2%80%99-c-di-AM(PS)2/pmc13405468-81-0-3
Average 96 stars, based on 1 article reviews
adu s100 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
cell growth medium 2  (PromoCell)
97
PromoCell cell growth medium 2
(A) Experimental design. All mice received two doses of HSV-1 gD mRNA administered one week apart. Mice were then assigned to receive PBS, mRNA-UB-E6/E7-gD, <t>ADU-S100,</t> or ADU-S100 + mRNA-UB-E6/E7-gD. One week after the final vaccination, mice were challenged subcutaneously with TC-1 cells. ADU-S100 (10 μg/dose) was administered intratumorally beginning 7 days after tumor implantation, when tumors reached approximately 5 × 5 mm, for a total of three treatments. (B) Tumor volumes of individual mice at the experimental endpoint. (C) Kaplan–Meier survival analysis of the indicated treatment groups. (D) Cytotoxic T-lymphocyte (CTL) activity against TC-1 target cells measured 24 h after assay initiation. Effector-to-target (E) ratios are indicated. (E) IFN-γ production in splenocyte culture supernatants measured by ELISA 24 h after assay initiation. E ratios are indicated. (F, G) Flow cytometric analysis of HPV16 E7-specific CD8 + T cells in tumor-infiltrating lymphocytes (F) and splenocytes (G), determined by HPV16 E7 tetramer staining. (H) Quantification of CD4 + and CD8 + tumor-infiltrating cells by immunohistochemistry. Positive cells were quantified using ImageJ from randomly selected microscopic fields and expressed as the number of positive cells per field. Statistical significance: ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Cell Growth Medium 2, supplied by PromoCell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+%E2%97%A6c/Endothelial+Cell+Growth+Medium+2/pmc12933747-279-9-14
Average 97 stars, based on 1 article reviews
cell growth medium 2 - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
◦ c  (Thermo Fisher)
99
Thermo Fisher ◦ c
(A) Experimental design. All mice received two doses of HSV-1 gD mRNA administered one week apart. Mice were then assigned to receive PBS, mRNA-UB-E6/E7-gD, <t>ADU-S100,</t> or ADU-S100 + mRNA-UB-E6/E7-gD. One week after the final vaccination, mice were challenged subcutaneously with TC-1 cells. ADU-S100 (10 μg/dose) was administered intratumorally beginning 7 days after tumor implantation, when tumors reached approximately 5 × 5 mm, for a total of three treatments. (B) Tumor volumes of individual mice at the experimental endpoint. (C) Kaplan–Meier survival analysis of the indicated treatment groups. (D) Cytotoxic T-lymphocyte (CTL) activity against TC-1 target cells measured 24 h after assay initiation. Effector-to-target (E) ratios are indicated. (E) IFN-γ production in splenocyte culture supernatants measured by ELISA 24 h after assay initiation. E ratios are indicated. (F, G) Flow cytometric analysis of HPV16 E7-specific CD8 + T cells in tumor-infiltrating lymphocytes (F) and splenocytes (G), determined by HPV16 E7 tetramer staining. (H) Quantification of CD4 + and CD8 + tumor-infiltrating cells by immunohistochemistry. Positive cells were quantified using ImageJ from randomly selected microscopic fields and expressed as the number of positive cells per field. Statistical significance: ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
◦ C, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+%E2%97%A6c/FURA+2-AM/pm42342000-85-43-56
Average 99 stars, based on 1 article reviews
◦ c - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
engineered exosomemediated near infrared ii region v 2 c quantum dot delivery  (Quantum Dot Inc)
86
Quantum Dot Inc engineered exosomemediated near infrared ii region v 2 c quantum dot delivery
(A) Experimental design. All mice received two doses of HSV-1 gD mRNA administered one week apart. Mice were then assigned to receive PBS, mRNA-UB-E6/E7-gD, <t>ADU-S100,</t> or ADU-S100 + mRNA-UB-E6/E7-gD. One week after the final vaccination, mice were challenged subcutaneously with TC-1 cells. ADU-S100 (10 μg/dose) was administered intratumorally beginning 7 days after tumor implantation, when tumors reached approximately 5 × 5 mm, for a total of three treatments. (B) Tumor volumes of individual mice at the experimental endpoint. (C) Kaplan–Meier survival analysis of the indicated treatment groups. (D) Cytotoxic T-lymphocyte (CTL) activity against TC-1 target cells measured 24 h after assay initiation. Effector-to-target (E) ratios are indicated. (E) IFN-γ production in splenocyte culture supernatants measured by ELISA 24 h after assay initiation. E ratios are indicated. (F, G) Flow cytometric analysis of HPV16 E7-specific CD8 + T cells in tumor-infiltrating lymphocytes (F) and splenocytes (G), determined by HPV16 E7 tetramer staining. (H) Quantification of CD4 + and CD8 + tumor-infiltrating cells by immunohistochemistry. Positive cells were quantified using ImageJ from randomly selected microscopic fields and expressed as the number of positive cells per field. Statistical significance: ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Engineered Exosomemediated Near Infrared Ii Region V 2 C Quantum Dot Delivery, supplied by Quantum Dot Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+%E2%97%A6c/pm42321851-2028-0-5
Average 86 stars, based on 1 article reviews
engineered exosomemediated near infrared ii region v 2 c quantum dot delivery - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
cell culture human be 2 c  (ATCC)
96
ATCC cell culture human be 2 c
(A) Experimental design. All mice received two doses of HSV-1 gD mRNA administered one week apart. Mice were then assigned to receive PBS, mRNA-UB-E6/E7-gD, <t>ADU-S100,</t> or ADU-S100 + mRNA-UB-E6/E7-gD. One week after the final vaccination, mice were challenged subcutaneously with TC-1 cells. ADU-S100 (10 μg/dose) was administered intratumorally beginning 7 days after tumor implantation, when tumors reached approximately 5 × 5 mm, for a total of three treatments. (B) Tumor volumes of individual mice at the experimental endpoint. (C) Kaplan–Meier survival analysis of the indicated treatment groups. (D) Cytotoxic T-lymphocyte (CTL) activity against TC-1 target cells measured 24 h after assay initiation. Effector-to-target (E) ratios are indicated. (E) IFN-γ production in splenocyte culture supernatants measured by ELISA 24 h after assay initiation. E ratios are indicated. (F, G) Flow cytometric analysis of HPV16 E7-specific CD8 + T cells in tumor-infiltrating lymphocytes (F) and splenocytes (G), determined by HPV16 E7 tetramer staining. (H) Quantification of CD4 + and CD8 + tumor-infiltrating cells by immunohistochemistry. Positive cells were quantified using ImageJ from randomly selected microscopic fields and expressed as the number of positive cells per field. Statistical significance: ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Cell Culture Human Be 2 C, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+%E2%97%A6c/BE(2)-C/pm42258445-51-3-15
Average 96 stars, based on 1 article reviews
cell culture human be 2 c - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
endothelial cell growth medium 2  (PromoCell)
98
PromoCell endothelial cell growth medium 2
(A) Experimental design. All mice received two doses of HSV-1 gD mRNA administered one week apart. Mice were then assigned to receive PBS, mRNA-UB-E6/E7-gD, <t>ADU-S100,</t> or ADU-S100 + mRNA-UB-E6/E7-gD. One week after the final vaccination, mice were challenged subcutaneously with TC-1 cells. ADU-S100 (10 μg/dose) was administered intratumorally beginning 7 days after tumor implantation, when tumors reached approximately 5 × 5 mm, for a total of three treatments. (B) Tumor volumes of individual mice at the experimental endpoint. (C) Kaplan–Meier survival analysis of the indicated treatment groups. (D) Cytotoxic T-lymphocyte (CTL) activity against TC-1 target cells measured 24 h after assay initiation. Effector-to-target (E) ratios are indicated. (E) IFN-γ production in splenocyte culture supernatants measured by ELISA 24 h after assay initiation. E ratios are indicated. (F, G) Flow cytometric analysis of HPV16 E7-specific CD8 + T cells in tumor-infiltrating lymphocytes (F) and splenocytes (G), determined by HPV16 E7 tetramer staining. (H) Quantification of CD4 + and CD8 + tumor-infiltrating cells by immunohistochemistry. Positive cells were quantified using ImageJ from randomly selected microscopic fields and expressed as the number of positive cells per field. Statistical significance: ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Endothelial Cell Growth Medium 2, supplied by PromoCell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+%E2%97%A6c/Endothelial+Cell+Growth+Medium+2/pm42265457-143-19-26
Average 98 stars, based on 1 article reviews
endothelial cell growth medium 2 - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier
i toluene c o p 2 10 200 1 200 2 c o p 2 spin coating b ref comp ex 3 s i c o p 2 spin coating c 3 cop2 is a cyclic olefin polymer  (Zeon Corporation)
86
Zeon Corporation i toluene c o p 2 10 200 1 200 2 c o p 2 spin coating b ref comp ex 3 s i c o p 2 spin coating c 3 cop2 is a cyclic olefin polymer
(A) Experimental design. All mice received two doses of HSV-1 gD mRNA administered one week apart. Mice were then assigned to receive PBS, mRNA-UB-E6/E7-gD, <t>ADU-S100,</t> or ADU-S100 + mRNA-UB-E6/E7-gD. One week after the final vaccination, mice were challenged subcutaneously with TC-1 cells. ADU-S100 (10 μg/dose) was administered intratumorally beginning 7 days after tumor implantation, when tumors reached approximately 5 × 5 mm, for a total of three treatments. (B) Tumor volumes of individual mice at the experimental endpoint. (C) Kaplan–Meier survival analysis of the indicated treatment groups. (D) Cytotoxic T-lymphocyte (CTL) activity against TC-1 target cells measured 24 h after assay initiation. Effector-to-target (E) ratios are indicated. (E) IFN-γ production in splenocyte culture supernatants measured by ELISA 24 h after assay initiation. E ratios are indicated. (F, G) Flow cytometric analysis of HPV16 E7-specific CD8 + T cells in tumor-infiltrating lymphocytes (F) and splenocytes (G), determined by HPV16 E7 tetramer staining. (H) Quantification of CD4 + and CD8 + tumor-infiltrating cells by immunohistochemistry. Positive cells were quantified using ImageJ from randomly selected microscopic fields and expressed as the number of positive cells per field. Statistical significance: ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
I Toluene C O P 2 10 200 1 200 2 C O P 2 Spin Coating B Ref Comp Ex 3 S I C O P 2 Spin Coating C 3 Cop2 Is A Cyclic Olefin Polymer, supplied by Zeon Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+%E2%97%A6c/cop2/us12649305-323-102-139
Average 86 stars, based on 1 article reviews
i toluene c o p 2 10 200 1 200 2 c o p 2 spin coating b ref comp ex 3 s i c o p 2 spin coating c 3 cop2 is a cyclic olefin polymer - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
msc growth medium 2  (PromoCell)
96
PromoCell msc growth medium 2
(A) Experimental design. All mice received two doses of HSV-1 gD mRNA administered one week apart. Mice were then assigned to receive PBS, mRNA-UB-E6/E7-gD, <t>ADU-S100,</t> or ADU-S100 + mRNA-UB-E6/E7-gD. One week after the final vaccination, mice were challenged subcutaneously with TC-1 cells. ADU-S100 (10 μg/dose) was administered intratumorally beginning 7 days after tumor implantation, when tumors reached approximately 5 × 5 mm, for a total of three treatments. (B) Tumor volumes of individual mice at the experimental endpoint. (C) Kaplan–Meier survival analysis of the indicated treatment groups. (D) Cytotoxic T-lymphocyte (CTL) activity against TC-1 target cells measured 24 h after assay initiation. Effector-to-target (E) ratios are indicated. (E) IFN-γ production in splenocyte culture supernatants measured by ELISA 24 h after assay initiation. E ratios are indicated. (F, G) Flow cytometric analysis of HPV16 E7-specific CD8 + T cells in tumor-infiltrating lymphocytes (F) and splenocytes (G), determined by HPV16 E7 tetramer staining. (H) Quantification of CD4 + and CD8 + tumor-infiltrating cells by immunohistochemistry. Positive cells were quantified using ImageJ from randomly selected microscopic fields and expressed as the number of positive cells per field. Statistical significance: ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Msc Growth Medium 2, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+%E2%97%A6c/Mesenchymal+Stem+Cell+Growth+Medium+2/us12648913-426-22-26
Average 96 stars, based on 1 article reviews
msc growth medium 2 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
medium  (PromoCell)
97
PromoCell medium
(A) Experimental design. All mice received two doses of HSV-1 gD mRNA administered one week apart. Mice were then assigned to receive PBS, mRNA-UB-E6/E7-gD, <t>ADU-S100,</t> or ADU-S100 + mRNA-UB-E6/E7-gD. One week after the final vaccination, mice were challenged subcutaneously with TC-1 cells. ADU-S100 (10 μg/dose) was administered intratumorally beginning 7 days after tumor implantation, when tumors reached approximately 5 × 5 mm, for a total of three treatments. (B) Tumor volumes of individual mice at the experimental endpoint. (C) Kaplan–Meier survival analysis of the indicated treatment groups. (D) Cytotoxic T-lymphocyte (CTL) activity against TC-1 target cells measured 24 h after assay initiation. Effector-to-target (E) ratios are indicated. (E) IFN-γ production in splenocyte culture supernatants measured by ELISA 24 h after assay initiation. E ratios are indicated. (F, G) Flow cytometric analysis of HPV16 E7-specific CD8 + T cells in tumor-infiltrating lymphocytes (F) and splenocytes (G), determined by HPV16 E7 tetramer staining. (H) Quantification of CD4 + and CD8 + tumor-infiltrating cells by immunohistochemistry. Positive cells were quantified using ImageJ from randomly selected microscopic fields and expressed as the number of positive cells per field. Statistical significance: ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+%E2%97%A6c/Endothelial+Cell+Growth+Medium+2+SupplementPack/pm42265457-143-30-26
Average 97 stars, based on 1 article reviews
medium - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier

Image Search Results


(A) Experimental design. All mice received two doses of HSV-1 gD mRNA administered one week apart. Mice were then assigned to receive PBS, mRNA-UB-E6/E7-gD, ADU-S100, or ADU-S100 + mRNA-UB-E6/E7-gD. One week after the final vaccination, mice were challenged subcutaneously with TC-1 cells. ADU-S100 (10 μg/dose) was administered intratumorally beginning 7 days after tumor implantation, when tumors reached approximately 5 × 5 mm, for a total of three treatments. (B) Tumor volumes of individual mice at the experimental endpoint. (C) Kaplan–Meier survival analysis of the indicated treatment groups. (D) Cytotoxic T-lymphocyte (CTL) activity against TC-1 target cells measured 24 h after assay initiation. Effector-to-target (E) ratios are indicated. (E) IFN-γ production in splenocyte culture supernatants measured by ELISA 24 h after assay initiation. E ratios are indicated. (F, G) Flow cytometric analysis of HPV16 E7-specific CD8 + T cells in tumor-infiltrating lymphocytes (F) and splenocytes (G), determined by HPV16 E7 tetramer staining. (H) Quantification of CD4 + and CD8 + tumor-infiltrating cells by immunohistochemistry. Positive cells were quantified using ImageJ from randomly selected microscopic fields and expressed as the number of positive cells per field. Statistical significance: ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Journal: Research Square

Article Title: Stepwise Enhancement of HPV16 E6/E7 mRNA Vaccine Efficacy Using HSV-1 gD Epitope Incorporation and Immune-Modulating Agents

doi: 10.21203/rs.3.rs-9890379/v1

Figure Lengend Snippet: (A) Experimental design. All mice received two doses of HSV-1 gD mRNA administered one week apart. Mice were then assigned to receive PBS, mRNA-UB-E6/E7-gD, ADU-S100, or ADU-S100 + mRNA-UB-E6/E7-gD. One week after the final vaccination, mice were challenged subcutaneously with TC-1 cells. ADU-S100 (10 μg/dose) was administered intratumorally beginning 7 days after tumor implantation, when tumors reached approximately 5 × 5 mm, for a total of three treatments. (B) Tumor volumes of individual mice at the experimental endpoint. (C) Kaplan–Meier survival analysis of the indicated treatment groups. (D) Cytotoxic T-lymphocyte (CTL) activity against TC-1 target cells measured 24 h after assay initiation. Effector-to-target (E) ratios are indicated. (E) IFN-γ production in splenocyte culture supernatants measured by ELISA 24 h after assay initiation. E ratios are indicated. (F, G) Flow cytometric analysis of HPV16 E7-specific CD8 + T cells in tumor-infiltrating lymphocytes (F) and splenocytes (G), determined by HPV16 E7 tetramer staining. (H) Quantification of CD4 + and CD8 + tumor-infiltrating cells by immunohistochemistry. Positive cells were quantified using ImageJ from randomly selected microscopic fields and expressed as the number of positive cells per field. Statistical significance: ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Article Snippet: ADU-S100 [2′3′-c-di-AM(PS)2 (Rp,Rp); MedChemExpress; cat. no. HY-12885] was administered intratumorally at 10 μg per mouse for three total doses given every 3 days.

Techniques: Tumor Implantation, Activity Assay, Enzyme-linked Immunosorbent Assay, Staining, Immunohistochemistry